Top

Published in:

Open Access 01-08-2000 | Commentary

Debate: The slippery slope of surrogate outcomes

Author: Ralph B D'Agostino Jr, PhD

Published in: Trials | Issue 2/2000

Abstract

Surrogate outcomes are frequently used in cardiovascular disease research. A concern is that changes in surrogate markers may not reflect changes in disease outcomes. Two recent clinical trials (Heart and Estrogen/Progestin Replacement Study [HERS], and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]) underscore this problem since their results contradicted what was expected based on the surrogate outcomes. The current regulatory policy to allow new therapies to be introduced onto the market based solely on surrogate outcomes may need to be reviewed.

Buehler JW, Mulinare J: Preventing neural tube defects. Pediatr Ann. 1997, 26: 535-539.CrossRefPubMed

Ewan PW: Prevention of peanut allergy. The Lancet. 2000, 352: 4-5.CrossRef

Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled. Ann Internal Med. 1996, 125: 605-613.CrossRef

Sobel BE, Furberg CD: Surrogates, semantics, and sensible public policy. Circulation. 1997, 95: 1661-1663.CrossRefPubMed

Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA. 1999, 282: 786-790. 10.1001/jama.282.8.786.CrossRefPubMed

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vitting-hoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998, 280: 605-613. 10.1001/jama.280.7.605.CrossRefPubMed

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. JAMA. 2000, 283: 1967-1975.CrossRef

Temple RJ: A regulatory authority's opinion about surrogate endpoints. In: Clinical Measurement in Drug Evaluation. Edited by Nimmo WS, Tucker GT. New York: Wiley;. 1995

Systolic Hypertension in Europe (Syst-Eur) Trial Investigators: Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997, 350: 757-764. 10.1016/S0140-6736(97)05381-6.CrossRef

10.

Kostis JB, Davis BR, Cutler JA, Grimm RH, Berge KG, Cohen JD, Lacy CR, Perry HM, Blaufox MD, Wassertheil-Smoller S, Black HR, Schron E, Berkson DM, Curb JD, Smith WM, McDonald R, Applegate WB: Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997, 278: 212-216. 10.1001/jama.278.3.212.CrossRefPubMed

Title: Debate: The slippery slope of surrogate outcomes
Author: Ralph B D'Agostino Jr, PhD
Publication date: 01-08-2000
Publisher: BioMed Central
Published in: Trials / Issue 2/2000
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/cvm-1-2-076

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Debate: The slippery slope of surrogate outcomes

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2000

An essential guide to the literature

Debate: Does it matter how you lower blood pressure?

Gene therapy for lipid disorders

Angiotensin receptor blockers in heart failure after the ELITE II trial

Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?

Low-molecular-weight heparins in the treatment of venous thromboembolism